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The underlying mechanism by which MyD88 regu-
lates the development of obesity, metainflamma-
tion, and insulin resistance (IR) remains unknown.
Global deletion of MyD88 in high-fat diet (HFD)-
fed mice resulted in increased weight gain,
impaired glucose homeostasis, elevated Dectin-1
expression in adipose tissue (AT), and proin-
flammatory CD11c+ AT macrophages (ATMs). Dec-
tin-1 KO mice were protected from diet-induced
obesity (DIO) and IR and had reduced CD11c+ AT
macrophages. Dectin-1 antagonist improved
glucose homeostasis and decreased CD11c+ AT
macrophages in chow- and HFD-fed MyD88 KO
mice. Dectin-1 agonist worsened glucose homeo-
stasis in MyD88 KO mice. Dectin-1 expression is
increased in AT from obese individuals. Together,
our data indicate that Dectin-1 regulates AT inflam-
mation by promoting CD11c+ AT macrophages
in the absence of MyD88 and identify a role for
Dectin-1 in chronic inflammatory states, such as
obesity. This suggests that Dectin-1 may have ther-2272 Cell Reports 19, 2272–2288, June 13, 2017 ª 2017 The Authors
This is an open access article under the CC BY license (http://creativeapeutic implications as a biomarker for metabolic
dysregulation in humans.INTRODUCTION
Obesity is characterized by excessive accumulation of white ad-
ipose tissue (AT) due in part to increased food intake, decreased
energy expenditure, and changes in lifestyle (Mokdad et al.,
2003). According to the World Health Organization (WHO),
39% of adults over 18 years are overweight and 13% are clini-
cally obese (WHO, 2015). A significant number of obese people
are also insulin resistant, and obesity is strongly correlated with
systemic low-grade inflammation (Belkina and Denis, 2010),
highlighting the role of the immune system in the development
of insulin resistance (IR).
Innate immune receptors, such as Toll-like receptors (TLRs),
are expressed in adipocytes and AT macrophages (ATMs)
and are important molecules that orchestrate inflammation-
induced IR. TLRs can signal through myeloid differentiation pri-
mary response gene 88 (MyD88) (Adachi et al., 1998), an adaptor
molecule expressed in immune cells, epithelial cells, and adipo-
cytes (Bhinder et al., 2014; Everard et al., 2014; Hoshi et al.,
2012; Yu et al., 2014). Some studies showed that whole-body
MyD88-deficient mice develop exacerbated IR in the absence.
commons.org/licenses/by/4.0/).
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of liver inflammation (Hosoi et al., 2010; Yokoyama et al., 2012).
By contrast, retinol binding protein 4 (RBP4) induces IR via a
MyD88-dependent pathway (Moraes-Vieira et al., 2016). How-
ever, how MyD88 contributes to obesity-induced IR and its ac-
tions in specific tissues are still not completely understood.
Dectin-1 is amember of the C-type lectin receptor (CLR) family
highly expressed in macrophages and dendritic cells (DCs)
(Herre et al., 2004) that recognizes b-glucans at fungal cell walls.
Dectin-1 requires interferon regulatory factor 5 (IRF5) for immune
responses (del Fresno et al., 2013), and IRF5 is necessary for dif-
ferentiation of M1 AT macrophages, which play a major role in
obesity-induced IR (Krausgruber et al., 2011). Furthermore, Dec-
tin-1 was reported to play a role in tumor cell recognition (Brown,
2006; Chiba et al., 2014). Dectin-1 is activated inmacrophages in
atherosclerotic plaques by vimentin (Thiagarajan et al., 2013), an
intermediate filament expressed in mesenchymal cells (Satelli
and Li, 2011).
Altogether, these data suggest that Dectin-1may be a key fac-
tor in the development of obesity-associated inflammation and
IR. Because Dectin-1 is expressed in macrophages and DCs,
we hypothesized that Dectin-1 modulates AT macrophage func-
tion and phenotype, contributing to the development of obesity
and IR.
Here, we observed that full deletion of MyD88 is sufficient
to cause obesity and IR in mice. However, these phenotypes
were partially reversed by depleting MyD88 specifically in
the myeloid cell compartment. In the absence of MyD88, we
observed that CD11c+ AT macrophages were highly present in
the AT, where Dectin-1 was upregulated. Yet, blocking Dectin-1
signaling, in both the lean and diet-induced obese (DIO) mice
improved glucose homeostasis and insulin sensitivity. Moreover,
Dectin-1-deficient macrophages displayed an anti-inflammatory
phenotype, and their conditioned media improved insulin sensi-
tivity in adipocytes. Finally, we found that increased expression
of Dectin-1 in the AT from the obese individuals was associated
with the enhanced expression of proinflammatory molecules.
Thus, our data indicate that Dectin-1 regulates AT inflammation
by promoting proinflammatory macrophage polarization in theFigure 1. MyD88 Is Necessary for Metabolic Homeostasis
(A) Body weight gain at end of diet.
(B) Analysis of body fat by DEXA (A, WT lean; B, WT DIO; C, MyD88 KO lean; D,
(C) Quantification of fat area (% of adiposity).
(D) Respiratory exchange ratio (RER) during day and night cycles.
(E) Glucose tolerance test (GTT).
(F) GTT area under the curve (AUC).
(G) Insulin tolerance test (ITT).
(H) ITT AUC.
(I) AT gene expression of Il-1b, Tnf-a, Il-6, Il-8, and Nlrp3.
(J) AT protein quantification of IL-1b, TNF-a, IL-6, and IL-18.
(K) Frequency of F4/80+CD11b+CD11c+ and F4/80+CD11b+CD206+ AT macro
(L) Absolute numbers of F4/80+CD11b+CD11c+ and F4/80+CD11b+CD206+ AT
(M) AT quantification of carbonyl content.
(N) Serum quantification of dextran fluorescein isothiocyanate (FITC).
(O) Serum quantification of LPS.
(P) Relative abundance of major commensal bacteria phyla in feces.
(Q) Principal coordinate (PC) analysis of gut microbiota composition based on wei
DIO mice.
(R) Heatmap based on relative abundance of OTUs in lean and DIO WT and MyD8
same genotype; #p% 0.05 versus all groups n = 5–8 mice. The data are represe
2274 Cell Reports 19, 2272–2288, June 13, 2017absence of MyD88. Dectin-1 may be an important therapeutic
target for the treatment of the chronic non-resolving inflamma-
tion associated with the obese and insulin resistant patients.
RESULTS
Absence of MyD88 Signaling Exacerbates Obesity-
Induced IR andPolarization of ATMacrophages toward a
Proinflammatory Phenotype
MyD88 signaling is a critical component for TLR signaling.
Although MyD88 has been studied in the context of obesity (Ho-
soi et al., 2010; Yokoyama et al., 2012), there are still some un-
solved questions to be accessed. DIO MyD88 knockout (KO)
mice gained more weight and had increased adiposity when
compared to the DIO wild-type (WT) animals (Figures 1A–1C
and S1A). DIO MyD88 KO mice had decreased VO2 and VCO2
and were more glucose intolerant and insulin resistant (Figures
1D–1H, S1B, and S1C). Moreover, insulin-stimulated AT Ser473-
AKT (serine 473 protein-kinase B) phosphorylation (Figure S1D),
glucose transporter type 4 (GLUT-4) protein expression (Fig-
ure S1D), ex vivo AT glucose uptake, and glucose oxidation (Fig-
ure S1E) were all decreased in the DIO MyD88 KO mice.
Together, these data demonstrate that MyD88 is necessary for
the maintenance of systemic glucose homeostasis.
Next, we investigated whether the absence of MyD88 would
affect the obesity-induced AT inflammation. DIO MyD88 KO
mice had decreased AT gene expression of Il-1b, Tnf-a, Il-6,
Il-18, and Nlrp3 (Figure 1I). Protein levels of interleukin 1 beta
(IL-1b), tumor necrosis factor alpha (TNF-a), interleukin 6 (IL-6),
and interleukin 18 (IL-18) were also decreased in the AT (Fig-
ure 1J) and serum (Figure S1F). Phosphorylation of c-Jun N-ter-
minal kinase (JNK) and IkB-a (nuclear factor of kappa light poly-
peptide gene enhancer in B-cells inhibitor, alpha) in the AT of the
DIO MyD88 KO mice were lower compared to the DIO WT mice
(Figure S1G).We next characterized the phenotype of the epidid-
ymal AT macrophages. We defined proinflammatory macro-
phages as the CD11c+ AT macrophages and anti-inflammatory
macrophages as the mannose receptor (cluster of differentiationMyD88 KO DIO).
phages.
macrophages/g of AT.
ghted (upper) and unweighted (lower) UniFRAc inWT andMyD88 KO, lean, and
8 KO mice at genus level. *p% 0.05 versus WT DIO; &p% 0.05 versus DIO on
nted as mean ± SEM.
206) (CD206+) AT macrophages, as previously described (Mo-
raes-Vieira et al., 2014). DIOMyD88 KOmice had increased total
numbers as well as percentage of the CD11c+ AT macrophages
and decreased numbers and percentages of the anti-inflamma-
tory CD206+ AT macrophages when compared to the DIO WT
mice (Figures 1K, 1L, and S1H). Similar results were observed
in liver (Figures S1I–S1Q). AT carbonyl content was decreased
in the DIO MyD88 KO mice (Figure 1M). This suggests that the
DIO MyD88 KO mice have reduced levels of oxidative injury.
Together, these data indicate that loss of MyD88 in the DIO
mice decreases AT inflammation despite increased levels of
the CD11c+ AT macrophages.
In obesity, alterations in gut microbiota composition are asso-
ciated with increased systemic lipopolysaccharide (LPS) levels,
which contribute to AT inflammation and the development of
IR (Castoldi et al., 2015a; Ley et al., 2005). DIO MyD88 KO
mice had increased gut permeability (Figures 1N and S2A–
S2H) and circulating LPS levels compared to the lean MyD88
KO mice (Figure 1O), but were not different when compared to
the DIOWTmice. Concomitantly, gut inflammatory markers, de-
fensins, and anti-microbial peptides were decreased in the DIO
MyD88 KO mice (Figures S2I–S2Q). High-fat diet (HFD)-fed
mice have an increased abundance of Firmicutes and reduced
Bacteroidetes in the feces (Cani et al., 2008). As reported, the
abundance of Bacteroidetes was decreased in both the DIO
WT and MyD88 KO mice, whereas Firmicutes was increased
compared to the lean animals (Figure 1P). Next, comparisons
between the groups were made using principal coordinate anal-
ysis (PCA) based on weighted and unweighted UniFRAc dis-
tances. A change in the microbiota was detected when the WT
and MyD88 KO mice were fed an HFD, which can be visualized
by the tight clustering of the microbial communities on axis prin-
cipal coordinate 1 (PC1) (Figures 1Q, S1R, and S1S). No differ-
ences were found between the mouse genotypes (Table S2).
We found increased Deltaproteobacteria abundance in both
DIO mice (Figure 1R) and Desulfovibrio was also increased in
both DIO mice (Figure S7A), and its abundance is related to
type 2 diabetes (Qin et al., 2012). Thus, HFD modulates gut mi-
crobiota diversity in both the WT and MyD88 KO mice when
compared to the controls. However, there was no difference in
microbiota diversity between the MyD88 KO and WT mice after
90 days on an HFD.
MyD88 Expression in Myeloid Cells, but Not in
Adipocytes, Is Necessary for the Development of
Obesity-Induced IR, AT Inflammation, and
Proinflammatory AT Macrophage Polarization
Although several cell types can signal through MyD88, their
individual contribution to obesity-associated inflammation and
metabolic deregulation is still unclear. Therefore, we investigated
the cell types in which MyD88 is necessary for the development
of obesity-induced inflammation and IR.
HFD-fed AdipoMyD88KO mice had similar body weights, AT
weight, glucose tolerance, and IR compared to the control DIO
AdipoMyD88WT mice (Figures 2A–2C and S3B). There was no
difference in the respiratory exchange ratio (RER) between the
adipose-specificMyD88KOmice and their controls (FigureS3C).
AT inflammation was also not different between the DIOAdipoMyD88KO and DIO AdipoMyD88WT mice (Figures 2D and
S3D–S3G). Intestinal permeability was increased in both the
DIO AdipoMyD88KO and DIO AdipoMyD88WT mice compared
to their lean controls (Figure 2E). Gut permeability was not
different between the HFD-fed AdipoMyD88 KO and the WT
controls (Figure 2E). These data indicate that MyD88 expression
in adipocytes does not contribute to the obesity-induced AT
inflammation, IR, or intestinal permeability.
We next hypothesized that MyD88 expression in macro-
phages may drive the proinflammatory and metabolic pheno-
types seen in the global MyD88 deletion in mice. Similar to
what was previously reported by Yu et al. (2014), the DIO
LyZMyD88KO mice were leaner (Figures 2F and S3K), had
improved glucose tolerance, and insulin sensitivity (Figures 2G
and 2H) without changes in RER when compared to the DIO
LyZMyD88WT mice (Figure S3L). Also, the DIO LyZMyD88KO
mice had reduced AT inflammation (Figures S3M and S3N),
with decreased numbers and percentages of the proinflamma-
tory CD11c+ AT macrophages compared to the controls on
the same diet (Figures 2I and S3O). The numbers and percent-
ages of the anti-inflammatory CD206+ AT macrophages were
markedly increased in the DIO LyZMyD88KO mice (Figures 2I
and S3P) compared to the DIO controls. DIO LyZMyD88KO
mice had reduced gut permeability compared to the DIO
LyZMyD88WT (Figure 2J). These results indicate that myeloid
expression of MyD88 is required for obesity-induced inflamma-
tion, control of energy expenditure, and subsequent IR develop-
ment. However, our finding that the global MyD88 KOmice were
heavier and IR when compared to the tissue-specific MyD88 KO
animals remained unclear. Thus, we hypothesized that another
molecule may be involved in this intricate network to drive meta-
bolic dysregulation.
Dectin-1 Levels Are Increased in AT and in AT
Macrophages of MyD88 KO Mice
First, we performed a proteomic analysis to identify differentially
expressed proteins in the AT of obese animals. We found that
molecules related to lipid metabolism were differentially ex-
pressed. Vimentin was significantly upregulated in the AT of
the DIO WT mice (Figures 3A and S4A), as well as in the DIO
global MyD88 KO mice (Figures 3B and S4B) compared to the
lean mice. Moreover, vimentin was also upregulated in the DIO
MyD88 KO mice compared to the DIO WT mice (Figures 3C
and S4C), but no difference was observed between the WT
and MyD88 KO lean mice (Figures 2D and S4C). Gene expres-
sion of Vimentin was consistently increased in the MyD88 KO
mice compared to the WT mice on the HFD (Figure 3E).
Since vimentin was previously associated to Dectin-1 (Thia-
garajan et al., 2013), and may act as an endogenous ligand for
Dectin-1, worsening IR in our model, we next analyzed the
expression of Dectin-1 in the AT of the WT and MyD88 KO
mice. Dectin-1 mRNA expression was increased in the AT of
the DIO MyD88 KO mice (Figure 3F). Moreover, the Dectin-1
adaptor molecule Syk (spleen tyrosine kinase) and the transcrip-
tion factor Irf5 were also increased in the DIO MyD88 KO mice
(Figures 3G and 3H). Dectin-1 and Syk were similarly increased
in the DIO AdipoMyD88KO and the DIO AdipoMyD88WT mice
(Figures S3H and S3I), while decreased in the DIO LyZMyD88KOCell Reports 19, 2272–2288, June 13, 2017 2275
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Figure 2. MyD88 Depletion in Myeloid Cells, but Not in AT, Protects Mice from Obesity Development and IR
(A) AdipoMyD88KO studies: body weight gain and body weight at the end of diet.
(B) Glucose tolerance test (GTT) and area under the curve (AUC).
(C) Insulin tolerance test (ITT) and AUC.
(D) Absolute numbers of F4/80+CD11b+CD11c+ and F4/80+CD11b+CD206+ ATmacrophages/g of AT (A, AdipoMyD88WT (Control) lean; B, AdipoMyD88WT (Control)
DIO; C, AdipoMyD88KO lean; D, AdipoMyD88KO DIO).
(E) Serum FITC dextran levels.
(F) LyZMyD88KO studies: body weight gain and body weight at the end of diet.
(G) GTT and the respective AUC.
(H) ITT and the respective AUC.
(I) Absolute numbers of F4/80+CD11b+CD11c+ and F4/80+CD11b+CD206+ ATmacrophages/g of AT (A, LyZMyD88WT (Control) lean; B, LyZMyD88WT (Control) DIO;
C, LyZMyD88KO lean; D, LyZMyD88KO DIO).
(J) Serum FITC dextran levels. *p% 0.05 versus MyD88WT DIO; &p% 0.05 versus DIO on same genotype; #p% 0.05 versus all groups. The data are represented
as mean ± SEM.
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compared to the DIO LyZMyD88WT (Figures S3Q and S3R).
Dectin-1 expression was upregulated in the CD11c+ AT macro-
phages from the epididymal AT of the DIOMyD88 KO compared
to the DIO WT mice, and it was also higher in the CD11c+ AT
macrophage of the lean MyD88 KO mice (Figures 3I–3K). These
data indicate that Dectin-1 expression is elevated during obesity
and in the global deficiency of MyD88 in mice. Therefore, Dec-
tin-1 may contribute to the development of IR and induction of
proinflammatory AT macrophage polarization.
Blockade of Dectin-1 Suppresses IR and CD11c+ AT
Macrophage Polarization
Because Dectin-1 expression is increased in the DIO mice,
we asked whether inhibition of Dectin-1 expression and/or
signaling could improve the AT inflammation, glucose intoler-
ance, and IR. HFD-fed Dectin-1 KO mice had improved glucose
tolerance and insulin sensitivity (Figures 4A and 4B). Chow- and
HFD-fed Dectin-1 KO mice displayed decreased numbers of
the proinflammatory CD11c+ AT macrophages (Figures 4D–
4F) and increased numbers of the anti-inflammatory CD206+
AT macrophages (Figures 4F and 4G). DIO Dectin-1 KO mice
had decreased gene and protein expression of the proinflam-
matory cytokines in the AT (Figures 4H–4K). Syk and Irf-5
mRNA expression were decreased and Arginase-1 was
increased in the DIO Dectin-1 KO mice (Figures 4L–4N). Gut
microbiota analysis showed decreased Proteobacteria and
increased Bacteroidetes in the DIO Dectin-1 KO mice
compared to the DIO WT mice (Figure 4O). Moreover, bacterial
proportions and communities in the lean and DIO Dectin-1 KO
mice were distinctly separated from the lean and DIO WT mice
on the PC1 and PC2 axes (Figures 4P, S1S, and S1T; Table S3).
The abundance of Deltaproteobacteria was decreased in the
DIO Dectin-1 KO mice compared to the DIO WT mice and
absent in the lean Dectin-1 KO mice (Figure 4Q). Desulfovibrio
was not detected in the Dectin-1 KO mice (Figure S7B). These
data support our hypothesis that Dectin-1 contributes to the
development of obesity and IR by regulating the CD11c+ AT
macrophage polarization and by modulating gut microbiota
populations of the HFD-fed mice.
Next, we treated the chow- and HFD-fed WT and MyD88
KO mice with laminarin or vehicle (PBS). Laminarin is a soluble
b-glucan from seaweed and binds to Dectin-1 without stimu-
lating downstream signaling pathways (Brown et al., 2002; Ger-
suk et al., 2006; Huang et al., 2012). After 5 weeks of treatment,
both theDIO and leanmice displayed improved insulin sensitivityFigure 3. Absence of MyD88 Augments Dectin-1 Expression in AT Mac
(A) Proteomics analysis in AT showing upregulated proteins in DIO WT versus lea
various types of interaction evidence).
(B) DIO MyD88 KO versus lean MyD88 KO.
(C and D) DIO MyD88 KO versus DIO WT (C) and lean MyD88 KO versus lean W
(E) AT gene expression of (Figure 1R), Vimentin.
(F–H) AT gene expression of Dectin-1 (F), Syk (G), and Irf-5 (H).
(I) Representative flow cytometry analysis of Dectin-1 in AT macrophages F4/80
B: WT DIO; C: MyD88 KO lean; D: MyD88 KO DIO).
(J) Dectin-1 expression in AT macrophages F4/80+CD11b+CD11c+ from WT an
(K) Median fluorescence intensity (MFI) of Dectin-1 expression in F4/80+CD11b+C
same genotype; @p% 0.05 versus WT lean. The data are represented as mean
2278 Cell Reports 19, 2272–2288, June 13, 2017and glucose tolerance (Figures 5A, 5B, 5H, 5I, S5A, S5B, S5H,
and S5I). Laminarin reduced the total numbers of the CD11c+
AT macrophages in the MyD88 KO and WT mice (Figures 5D,
5K, S5D, and S5K) without affecting the numbers of the
CD206+ AT macrophages in the DIO or lean WT mice (Figures
5E and S5E). However, the numbers of the CD206+ AT macro-
phages in both the lean and DIOMyD88 KOmice were increased
(Figures 5L and S5L). Laminarin reduced Dectin-1 expression in
theCD11c+ATmacrophages from theWT andMyD88KOon the
chow and HFD fed mice (Figures 5F, 5M, S5F, and S5M).
Furthermore, gene expression of Il-6 was decreased in both
the chow- and HFD-fed WT mice, but no difference was
observed in both the laminarin-treated DIO and lean MyD88
KO mice (Figures 5G, 5N, S5G, and S5N). We found reduced
AT Irf5 and Syk gene expression in all the laminarin-treated
mice compared to vehicle-treated mice (Figures 5G, 5N, S5G,
and S5N). In both lean and DIO WT and MyD88 KO mice, AT
expression of Arginase-1was increased after the laminarin treat-
ment compared to the vehicle mice (Figures 5G, 5N, S5G, and
S5N). Thus, inhibition of Dectin-1 protects mice from IR, and
this is associated with decreased proinflammatory CD11c+ AT
macrophages.
We next determined the effect of laminarin on the gut micro-
biota abundance and diversity in the lean and DIO WT and
MyD88 KO mice. We did not observe an effect of laminarin on
phyla abundance in the DIO and lean mice compared to the
vehicle-control mice (Figure 5O). There were changes in bacte-
rial proportions and communities in the WT and MyD88 KO
mice when comparing the diet and genotypes after 5 weeks of
HFD feeding (Figure 5P; Table S4). However, laminarin treatment
did not induce changes compared to the vehicle-treated mice
(Figures 5P, S5O, and S5P; Table S4). Blockade of Dectin-1
with laminarin-induced small changes in Deltaproteobacteria
operational taxonomic units (OTUs) (Figure 5Q). Altogether,
these data suggest that Laminarin treatment does not induce
gut microbiota changes after 5 weeks of the HFD feeding and
the laminarin effects are independent of the gut microbiota
alterations.
We performed internal transcribed spacer (ITS) sequencing on
the feces from both the lean and DIOMyD88 KO andWTmice to
rule out any type of fungal response or dependency. We did not
detect fungi in the feces of the laminarin- or vehicle-treated mice
(Figure S2U). Thus, blocking Dectin-1 results in beneficial effects
on the inflammation and glucose homeostasis, after 5 weeks of
treatment, without affecting the gut microbiota.rophages
n WT (STRING network view: colored lines between the proteins indicate the
T (D).
+CD11b+CD11c+ from WT and MyD88 KO, lean, and DIO mice (A: WT lean;
d MyD88 KO, lean, and DIO mice.
D11c+ AT macrophages. *p% 0.05 versus WT DIO; &p% 0.05 versus DIO on
± SEM.
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Dectin-1 Agonist Treatment Worsens IR and CD11c+ AT
Macrophage Polarization
Since Dectin-1 antagonism prevented AT macrophage polariza-
tion toward a proinflammatory profile, we asked whether
Dectin-1 activation could worsen IR. Curdlan-treated lean and
DIO MyD88 KO and WT mice had worsened insulin sensitivity
and glucose tolerance (Figures 6A, 6B, 6H, 6I, S6A, S6B, S6H,
and S6I) and increased serum LPS levels (Figures 6C, 6J, S6C,
and S6J). Curdlan increased the numbers of the CD11c+ AT
macrophages (Figures 6D, 6K, S6D, and S6K) and decreased
the number of the CD206+ AT macrophage compared to the un-
treatedmice (Figures 6E, 6L, S6E, and S6L). Curdlan treatment in
the lean and DIO WT and MyD88 KO mice increased expression
of Dectin-1 in the CD11c+ AT macrophages (Figures 6F, 6M,
S6F, and S6M) and augmented expression of Il-6, Irf5, Arg-1,
and Syk in the AT (Figures 6G, 6N, S6G, and S6N).
We next asked if curdlan treatment could alter the gut micro-
biota. Curdlan treatment did not change the abundances of
Bacteroidetes or Firmicutes compared to the vehicle-treated
DIO and lean animals (Figure 6O). PC analysis showed differ-
ences among the groups in diet and genotype, after 5 weeks
of treatment (Figure 6P; Table S5). A trend toward clustering of
samples from the curdlan-treated and vehicle-treated groups
was observed, especially using weighted UniFRAc distances,
however, no statistically significant differences were found (Fig-
ures 6P, S6O, and S6P; Table S5). OTU analysis showed that
activation of Dectin-1 by curdlan did not restoreDeltaproteobac-
teria (Figure 6Q). These data indicate that Dectin-1 activation
induced the CD11c+ AT macrophage polarization, increased
AT inflammation, and impaired glucose homeostasis without
changing the gut microbiota after 5 weeks of treatment.
Dectin-1 Increases M1 Macrophages Polarization and
Increases Insulin Sensitivity in Adipocytes In Vitro
To confirm the role of Dectin-1 on macrophage polarization,
we differentiated bone marrow-derived macrophages (BMDMs)
from the Dectin-1 KO and WT mice. Dectin-1 KO BMDMs had
decreased M1 polarization under LPS and interferon (IFN)-g
stimulation (Figure 7A) and expressed lower levels of Irf5 and
Il-6mRNA (Figures 7B and 7C). Dectin-1 KO BMDMs stimulated
with the IL-4 and IL-13 polarized toward an M2 phenotype and
had reduced Il-6 and increasedArginase-1 gene expression (Fig-
ures 7D and 7F). We also tested the capacity of the M1 BMDMsFigure 4. Dectin-1 KO Mice Are Protected from Metabolic Syndrome
(A) Glucose tolerance test (GTT) and area under the curve (AUC).
(B) Insulin tolerance test (ITT) and AUC.
(C) Serum LPS quantification.
(D) Absolute number of F4/80+CD11b+CD11c+ AT macrophages/g of AT.
(E) Absolute numbers of F4/80+CD11b+CD206+ AT macrophages/g of AT.
(F) Frequency of F4/80+CD11b+CD11c+ AT macrophages.
(G) Frequency of F4/80+CD11b+CD206+ AT macrophages.
(H) AT protein quantification of IL-1b, TNF-a, IL-6, and IL-18.
(I–N) AT gene expression of Il-1b (I), Tnf-a (J), Il-6 (K), Syk (L), Irf5 (M), and Argina
(O) Relative abundance of major commensal bacteria phyla in feces.
(P) Principal coordinate (PC) analysis of gutmicrobiota composition based onweig
DIO mice.
(Q) Heatmap based on relative abundance of OTUs in lean and DIO WT and Dec
*p% 0.05 versus WT DIO; &p% 0.05 versus DIO on same genotype; #p% 0.05
2280 Cell Reports 19, 2272–2288, June 13, 2017from the Dectin-1 KO mice to impair insulin signaling in adipo-
cytes. 3T3-L1 adipocytes differentiated in vitro, were cultured
during 24 hr with conditioned media from activated M1 BMDMs
from theWT and Dectin-1 KOmice. Ser473AKT phosphorylation
was increased in adipocytes treatedwith the Dectin-1 KO-condi-
tioned media compared to the adipocytes treated with condi-
tioned media from the WT M1 BMDMs (Figure 7G). These data
suggest that Dectin-1 expression drivesM1macrophages polar-
ization and may contribute to impaired insulin sensitivity in adi-
pocytes in vitro.
AT from Obese Individuals Displays Increased Dectin-1
Expression
We next aimed to determine whether the expression level of
Dectin-1 in the AT from obese humans (Table S1) correlates
with the parameters of systemic metabolic dysregulation and
inflammation. Dectin-1 gene and protein expression were
increased in the mesenteric AT of obese individuals compared
to the lean controls (Figures 7H and 7M). Similarly, Il-6 expres-
sion was increased in the obese AT (Figure 7I). Dectin-1 expres-
sion positively correlated with BMI, serum triglycerides, and C
reactive protein (CRP) levels in the obese individuals (Figures
7J–7L). In addition, vimentin was increased in the AT from
the obese individuals (Figure 7M). Co-immunoprecipitation of
Dectin-1 and vimentin from the AT of obese individuals showed
a direct interaction between these two proteins (Figure 7N).
These data indicate that Dectin-1 expression is increased in
obesity and influences the AT IR in humans.
DISCUSSION
The expression of the proinflammatory cytokines in the AT is
increased in models of HFD-induced obesity (Castoldi et al.,
2015b; Hotamisligil et al., 1996; Trayhurn, 2005). Proinflamma-
tory CD11c+ macrophages also accumulate in the AT of obese
mice (Amano et al., 2014; Oh et al., 2012; Shaul et al., 2010).
Innate immune receptors can sense several alarmins in the
obese state, which contributes to the initiation of the inflamma-
tory response (Moraes-Vieira et al., 2016). The MyD88 pathway
is a central component of this immune response.
We show that the whole-bodyMyD88 KOmice fed an HFD are
heavier and more insulin resistant without increased systemic or
AT inflammation. This suggests that the global MyD88 signalingse-1 (N), respectively.
hted (upper) and unweighted (lower) UniFRAc inWT andDectin-1 KO, lean, and
tin-1 KO mice at genus level.
versus all groups n = 5–8 mice. The data are represented as mean ± SEM.
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contributes to regulating the immune response in obesity,
but may have differential roles in a tissue-dependent manner.
MyD88 signaling plays an important role in fibrosis and athero-
sclerosis (Bjo¨rkbacka et al., 2004; Braga et al., 2012), and
blockade of MyD88 increases the severity and mortality of colitis
in mice (Rakoff-Nahoum et al., 2004). Altogether, this suggests
that MyD88 has different effects in acute versus chronic inflam-
matory conditions.
We observed that depletion of MyD88 in adipocytes does not
protect mice from obesity and IR. In contrast, the absence of
MyD88 in myeloid cells improved insulin sensitivity in the HFD-
fed mice. These mice had decreased CD11c+ AT macrophage
numbers and improved intestinal barrier function. Thus, deletion
of MyD88 in myeloid cells improved the AT inflammation and
systemic insulin sensitivity. This contrasts the phenotype of our
and other reports of the global MyD88 KO mice (Hosoi et al.,
2010; Yokoyama et al., 2012) and contrasts the findings indi-
cating that depletion of MyD88 in myeloid cells does not protect
mice from obesity-induced IR (Kubinak et al., 2015). However,
we cannot exclude the environmental factors at different animal
facilities.
Our experiments on depletion of MyD88 in adipocytes and
myeloid cells does not exclude the interference of MyD88
expression in other cell types such as epithelial intestinal cells
and lymphocytes, which may contribute to the observed meta-
bolic phenotypes in these mice.
Macrophages play an essential role in obesity-induced IR.
Here, the HFD-fed LyZMyD88KO mice demonstrate that loss of
MyD88 function in myeloid cells prevents CD11c+ AT macro-
phage polarization, which may account for the improvement
in body weight gain, adiposity, glucose homeostasis, and gut
permeability. Thus, an MyD88-independent pathway may be
involved in the regulation of inflammation-induced metabolic
syndrome.
Dectin-1 is involved in fungal infections and was recently re-
ported to play a role in anti-tumor immune responses (Chiba
et al., 2014). Moreover, vimentin levels were increased in athero-
sclerotic plaques and can bind to and activate Dectin-1 in mac-
rophages (Thiagarajan et al., 2013). The role of vimentin inFigure 5. Dectin-1 Antagonist Treatment Protects Mice from Developi
(A) Insulin tolerance test (ITT) and area under the curve (AUC) of DIO WT mice co
(B) Glucose tolerance test (GTT) and AUC.
(C) Serum LPS quantification.
(D) Total numbers of F4/80+CD11b+CD206+ AT macrophages/g of AT.
(E) Total numbers of F4/80+CD11b+CD206+ AT macrophages/g of AT.
(F) Expression of Dectin-1 in F4/80+CD11b+CD11c+ AT macrophages (A, WT D
(G) AT gene expression of Il-6, Irf-5, Arginase-1, and Syk.
(H) ITT and AUC of DIO MyD88 KO mice control (vehicle-treated) and 5 weeks tr
(I) GTT and AUC.
(J) Serum LPS quantification.
(K) Total numbers of F4/80+CD11b+CD11c+ AT macrophages/g of AT.
(L) Total numbers of F480+CD11b+CD206+ AT macrophages/g of AT.
(M) Expression of Dectin-1 in F4/80+CD11b+CD11c+ AT macrophages (A, MyD8
(N) AT gene expression of Il-6, Irf-5, Arginase-1, and Syk.
(O) Relative abundance of major commensal bacteria phyla in feces.
(P) Principal coordinate (PC) analysis of gut microbiota composition based on we
KO laminarin- and vehicle-treated mice.
(Q) Heatmap based on relative abundance of OTUs in lean and DIO WT and My
C57BL/6 + PBS, n = 5 each group. The data are represented as mean ± SEM.
2282 Cell Reports 19, 2272–2288, June 13, 2017obesity is unknown. We hypothesized that loss of functional
MyD88 may induce other factors, such as vimentin in the AT,
to induce IR independent of the classical MyD88-dependent in-
flammatory pathway. We performed proteomics analysis in the
AT and found that vimentin was upregulated in the DIO MyD88
KOmice. Therefore, vimentin may in part drive the HFD-induced
obesity by directly binding to and activating Dectin-1 (Thiagara-
jan et al., 2013). Hypoxia is commonly observed in the AT from
the HFD-fed mice and has been reported to regulate vimentin
expression (Satelli and Li, 2011). Increased vimentin levels may
be due to the AT hypoxia in our HFD-induced obesity models.
Furthermore, hypoxia was shown to increase the expression of
Annexin A1 (ANXA1), which induces prostate cancer cell prolifer-
ation (Bizzarro et al., 2016). Our proteomics analysis showed a
positive interaction between ANXA and vimentin in the AT of
the WT and MyD88 KO DIO mice, suggesting that vimentin is
increased during obesity due to low oxygen availability in the
AT. Fungal microbiota was undetectable by our ITS sequencing
analysis, further validating the role of Dectin-1 and vimentin in
obesity-driven inflammation and impaired glucose homeostasis.
During fungal infection, Dectin-1 affects macrophage polariza-
tion by activating IRF5 in the Dectin-Syk pathway (del Fresno
et al., 2013). IRF5 is a transcription factor that regulates proin-
flammatory CD11c+ macrophage differentiation (Weiss et al.,
2013). We found that the Dectin-1 adaptor molecules Syk and
Irf5 are upregulated in the AT of the obese MyD88 KO mice
and demonstrate that Dectin-1 activation contributes to the
development of IR. Furthermore, Dectin-1 levels in the CD11c+
AT macrophages were increased in the lean and obese MyD88
KO mice, while the Dectin-1 KO mice were protected from
obesity and IR. Blocking Dectin-1 improved insulin sensitivity
in the mice fed an HFD and treating the chow- and HFD-fed
WT andMyD88KOmice with the Dectin-1-specific agonist wors-
ened glucose homeostasis. Altogether, these data support our
idea that even in the absence of MyD88, antagonizing Dectin-1
is sufficient to restore the glucose homeostasis context of
MyD88 deletion.
Activation of Dectin-1 increases the TNF-a production in hu-
man macrophages (Ferwerda et al., 2008). Also, the Dectin-1ng IR and Reduces CD11c+ AT Macrophages Polarization
ntrol (vehicle-treated) and 5 weeks treated with laminarin.
IO + PBS; B, WT DIO + Laminarin).
eated with laminarin.
8 KO DIO + PBS; B, MyD88 KO DIO + Laminarin).
ighted (upper) and unweighted (lower) UniFrac in lean and DIO WT and MyD88
D88 KO, laminarin- and vehicle-treated mice at genus level. *p < 0.05 versus
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agonist curdlan increases the expression of cell surface markers
specific to macrophage and the DCs activation (cluster differen-
tiation [CD]40 and CD86) and increases cytokine release by the
DCs (Kim et al., 2016). Moreover, Dectin-1 activation by b-glucan
is sufficient to polarize tumor-associated macrophages from a
M2 to an M1 phenotype (Liu et al., 2015). These data support
our hypothesis that activation of Dectin-1, even in the absence
of the global MyD88 in the HFD-fed mice, is sufficient to drive
CD11c+ AT macrophage polarization and subsequent onset
of IR. Here, the Dectin-1 KO mice also have reduced CD11c+
AT macrophage numbers. Laminarin treatment decreased the
proinflammatory profile of the CD11c+ AT macrophages in the
lean and DIO MyD88 KO and in WT mice, while blocking Dec-
tin-1 increased anti-inflammatory CD206+ AT macrophage
numbers. Conversely, activation of Dectin-1 increased the
CD11c+ AT macrophages in all genotypes. Here, we show that
Dectin-1 inhibition decreases the number of proinflammatory
CD11c+ AT macrophages, which is consistent with Dectin-1-
dependent proinflammatory macrophage polarization in tumor
and fungal infection models (Liu et al., 2015; Loures et al., 2014).
Our data show that Dectin-1 directly mediates macrophage
polarization and subsequently affects insulin sensitivity. These
data indicate that Dectin-1 activation is involved in CD11c+ AT
macrophages accumulation and inflammation-induced IR.
It is well known that changes in the gut microbiota are involved
in the pathogenesis of obesity and IR (Castoldi et al., 2015a; Ley
et al., 2005). Obesity is associated with increased Firmicutes
and decreased Bacteroidetes abundance (Ley et al., 2005). We
showed that the HFD, but not the absence of MyD88, induces
changes on the gut microbiota communities after 90 days of
HFD feeding. However, 5 weeks of HFD-feeding induced differ-
ences in the gut microbial communities between the WT and
MyD88 KO mice. For instance, we found that Deltaproteobacte-
ria was increased in both the obese WT and MyD88 KO mice,
which is also consistently increased in obesity induced by HFD
in our and previous studies (Lecomte et al., 2015). Increased
prevalence of Deltaproteobacteria, specifically the Desulfovibrio
genus, is observed in type 2 diabetic patients (Qin et al., 2012)Figure 6. Dectin-1 Agonist Treatment Increases IR and CD11c+ AT Ma
(A) Insulin tolerance test (ITT) and area under the curve (AUC) of DIO WT mice co
(B) Glucose tolerance test (GTT) and AUC.
(C) Serum LPS quantification.
(D) Total numbers of F4/80+CD11b+CD11c+ AT macrophages/g of AT.
(E) Total numbers of F4/80+CD11b+CD206+ AT macrophages/g of AT.
(F) Expression of Dectin-1 in F4/80+CD11b+CD11c+ AT macrophages (A, WT D
(G) AT gene expression of Il-6, Irf-5, Arginase-1, and Syk.
(H) ITT and AUC of DIO MyD88 KO mice control (vehicle-treated) and 5 weeks tr
(I) GTT and AUC.
(J) Serum LPS quantification.
(K) Total numbers of F4/80+CD11b+CD11c+ AT macrophages/g of AT.
(L) Total numbers of F4/80+CD11b+CD206+ AT macrophages/g of AT.
(M) Expression of Dectin-1 in F4/80+CD11b+CD11c+ AT macrophages (A, MyD8
(N) AT gene expression of Il-6, Irf-5, Arginase-1, and Syk.
(O) Relative abundance of major commensal bacteria phyla in feces.
(P) Principal coordinate (PC) analysis of gut microbiota composition based on we
and vehicle-treated mice.
(Q) Heatmap based on relative abundance of OTUs in lean and DIO WT and My
C57BL/6 + PBS, n = 5 each group. The data are represented as mean ± SEM.
2284 Cell Reports 19, 2272–2288, June 13, 2017and in patients with persistent diabetes after bariatric surgery
(Murphy et al., 2016). This is consistent with our results in obese
and insulin resistant mice. Together, our results here show that
MyD88 does not control the gut microbial communities after
90 days of HFD-feeding.
The role of Dectin-1 in obesity and its effects on the gut micro-
biota are unclear. HFD-fed Dectin-1 KOmice showed significant
differences in bacterial communities compared to the WT mice
in both the lean and DIO states having increased Bacteroidetes
and decreased Deltaproteobacteria abundances. However,
laminarin and curdlan were not able to induce changes in the
gut microbial communities after 5 weeks of treatment, which
may be due to the short treatment period. These data support
a role of Dectin-1 activation in regulating insulin sensitivity.
Dectin-1 expression is increased in the AT from the obese in-
dividuals and is positively correlated with BMI, CRP, and triglyc-
erides levels. This suggests that Dectin-1 may have therapeutic
implications as a biomarker for metabolic dysregulation in hu-
mans. Dectin-1 is expressed in peripheral monocytes from
type 2 diabetic patients with poor glycemic control (Cortez-Espi-
nosa et al., 2012). Furthermore, the expression of vimentin in the
AT from the obese individuals was increased, and we found that
Dectin-1 and vimentin directly interact in the human AT. This
highlights potential applications for Dectin-1 in the development
of therapeutic targets for obesity in humans. However, we recog-
nize that other endogenous ligands may also stimulate Dectin-1
in obese conditions. More research is needed to further elucidate
how Dectin-1 is regulated in obesogenic conditions.
In conclusion, we show that Dectin-1 is important for sys-
temic glucose homeostasis by controlling proinflammatory AT
macrophage accumulation and by maintaining a healthy gut mi-
crobiota profile. We also show that MyD88/Dectin-1 regulation
is critical for maintaining glucose homeostasis and systemic
inflammation in mice and humans. Collectively, our data provide
insight into the roles of MyD88 and Dectin-1 and support a
pathway involved in the AT inflammation, which may lead to
the development of new therapeutic approaches to treat insulin
resistant individuals.crophages Polarization
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IO + PBS; B, WT DIO + curdlan).
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Figure 7. Dectin-1 Is Correlated to Proinflammatory Macrophages Polarization and Obesity in Humans
(A) CD86 expression in polarized M1 BMDMs (IFN-g + LPS) from WT and Dectin-1 KO mice.
(B and C) Gene expression of irf-5 (B) and il-6 in M1 macrophages (C).
(D) CD206 expression in polarized M2 BMDMs (IL-4 + IL-13) from WT and Dectin-1 KO mice.
(legend continued on next page)
Cell Reports 19, 2272–2288, June 13, 2017 2285
EXPERIMENTAL PROCEDURES
Animal Studies
Mouse studies were conducted in accordance with federal guidelines. The
Institutional Animal Care and Use Committee (Institute of Biomedical Science,
University of Sao Paulo, Sao Paulo, Brazil) approved all studies. Studies were
performed on age- and sex-matched littermates. Malemice, 4–8 weeks old, all
C57BL/6, MyD88 KO, Dectin-1 KO, and WT. Adiponectincre+ MyD88flox/flox
(AdipoMyD88KO) mice and Lysozymecre+ MyD88flox/flox (LyZMyD88KO) were
also used in this study. For more details, see Supplemental Experimental
Procedures.
Human Studies
Mesenteric AT was obtained of six lean and seven obese patients from Hospi-
tal Universita´rio/University of S~ao Paulo, SP, Brazil under the ethics committee
number: CEP 1390/14 and CAEE: 20643513.9.000.5467. The individuals were
seven males and six females, age range 28–65 years old.
Obesity Induction
Obesity was induced by the HFD (rodent diet 45% kcal from fat, 20% kcal from
protein, and 35%kcal from carbohydrate, Research Diets) irradiated. Themice
were fed for 12 weeks starting from the sixth week of life. For more details, see
Supplemental Experimental Procedures.
Metabolic Parameters Analysis
Peripheral response to glucose was assessed by glucose tolerance test (GTT)
in mice fasted for 12 hr and injected with 2 g/kg of glucose. The insulin
response was examined by insulin tolerance test (ITT) after fasting mice for
6 hr and injection of 0.8 U/kg of insulin. For more details, see Supplemental
Experimental Procedures.
Purification of Infiltrating Cells in AT and Evaluation of Cellular
Phenotypes by Flow Cytometry
Cells from the AT were purified and stained with the following antibody panel:
anti-CD45, CD11b, F4/80, CD11c, and CD206 diluted 1:100 (BioLegend). M1
macrophages were characterized by expression of CD11c concomitant with
F4/80 and CD11b markers and M2 macrophages by expression of CD206
concomitant with F4/80 and CD11b markers. Dectin-1 positive cells
were identified using anti-Dectin-1/CLEC7A diluted 1:100 (BioLegend). The
characterization of subpopulations of leukocytes was performed on the
FACSCANTO II machine (BD), and data analysis was performed with FlowJo
9.5.3 software (Treestar). For more details, see Supplemental Experimental
Procedures.
Gene Expression
After preparation of cDNA, the quantification of gene expression by real-
time PCR was performed. Amplification conditions were standardized for
each transcript. A comparative relationship between reaction cycles (CT)
was used to determine gene expression relative to HPRT control (house-
keeping gene). For more details, see Supplemental Experimental Procedures.
Laminarin and Curdlan Treatment
Laminarin (SIGMA) and Curdlan (SIGMA) diluted in sterile PBS 13were admin-
istered intraperitoneally (250 mg/kg) and (15 mg/mouse) respectively three
times a week during 5 weeks. PBS was administered as vehicle. For more
details, see Supplemental Experimental Procedures.(E and F) Gene expression of Arginase-1 (E) and Il-6 in M2 macrophages (F).
(G) Adipocytes p-AKT ser473 quantification after 24 hr cultured with M0 and M1
(H and I) Analysis of genic expression of Dectin-1 (H) and Il-6 in mesenteric AT fr
(J) Analysis of the correlation between Dectin-1 gene expression and BMI values
(K) Analysis of the correlation between Dectin-1 gene expression and triglyceride
(L) Analysis of the correlation between Dectin-1 gene expression and CRP.
(M) Protein expression of vimentin and Dectin-1 in AT from lean and obese huma
(N) Human AT co-immunoprecipitation of Dectin-1 and western blotting showing
For human studies, *p% 0.05 versus lean individuals, n = 6–7 each group. The d
2286 Cell Reports 19, 2272–2288, June 13, 2017Analysis of Gut Microbiota Composition
For more details, see Supplemental Experimental Procedures.
BMDMs
Mouse tibia and femurwere harvested and cultivated inDMEMcontaining 10%
fetal bovine serum, 1% penicillin/streptomycin (pen/strep), and 20 ng/mL
of M-CSF (PeproTech). After 6 days, the medium was replaced and cells
were stimulated with addition of LPS (100 ng/mL), plus IFN-g (10 ng/mL,
PeproTech) for M1 polarization or IL-4 (10 ng/mL, PeproTech), plus IL-13
(10 ng/mL, PeproTech) for M2 polarization for 24 hr. For more details, see Sup-
plemental Experimental Procedures.
Statistics
All values are given as means ± SEM. Differences among the groups were
compared using ANOVA with Tukey post-test for multiple comparisons and
Student’s t test when there were only two groups. All statistical analysis
were performed using GraphPad PRISM 6 software, and the differences
were considered significant when p < 0.05.
ACCESSION NUMBERS
The accession numbers for the gut microbiota sequencing and prote-
omics reported in this paper are NCBI: PRJNA386634 and Peptide Atlas:
PASS01020.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.05.059.
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